Pepsi vs Pfizer

8-K Financial Filing Analysis for Pepsi (2026-09-17)

On September 17, 2026, PepsiCo, Inc. announced the election of Joaquin Duato, Chairman and CEO of Johnson & Johnson, as an independent member of its Board of Directors, effective December 1, 2026. Mr. Duato will also serve on the Board's Audit Committee. Under PepsiCo's non-employee director compensation program, Mr. Duato will receive an initial stock award of 1,000 shares of Common Stock, a prorated annual equity award in phantom stock units valued at $166,667 on the effective date, and standard director cash compensation, including a semi-annual cash retainer payment of $60,000 payable in June 2027.

• Joaquin Duato (Chairman & CEO of Johnson & Johnson) elected as an independent director and Audit Committee member, effective December 1, 2026.
• Initial equity grant of 1,000 PepsiCo Common Stock shares plus a prorated phantom stock unit award valued at $166,667 upon appointment.
• Director cash retainer set with the initial semi-annual installment of $60,000 scheduled for payment in June 2027.

Kraft Heinz CMO: Joy Improves Marketing

Adweek’s Marketing Vanguard series at Cannes Lions 2026 features an interview between host Jenny Rooney and Todd Kaplan, chief marketing officer, North America at The Kraft Heinz Company. Kaplan argues that marketing should be fun, and that joy, looseness and cultural fluency produce stronger creative work as paid media becomes easier to ignore. The vidcast—recorded live at Cannes and presented in partnership with Edelman—also covers Kraft Heinz’s portfolio marketing across more than 70 brands, the company’s Cannes-recognized creative work (including Heinz’s Grand Prix-winning “Looks Familiar”), and Kaplan’s prior role as Pepsi’s CMO.

• Todd Kaplan is chief marketing officer, North America at The Kraft Heinz Company.
• Kaplan leads marketing across a $25 billion food and beverage portfolio spanning more than 70 brands and 50 categories at Kraft Heinz.
• The vidcast episode was recorded live during Cannes Lions 2026 and presented in partnership with Edelman.

Pepsi launches ice-cream‑flavored colas

Pepsi has launched three limited-edition ice-cream‑inspired zero sugar cola flavors — Cherry & Vanilla, Raspberry Ripple and Salted Caramel — supported by a comedic campaign starring an animated ice‑cream pigeon called Pidge. The campaign includes a TV commercial, nationwide sampling tour and immersive pop-up experiences in London and Brighton. Creative and production credits listed in the article include Sips & Bites (creative agency), Busy Bee (production), Bark Soho (audio post) and OMD (media agency). The Drum published the story on July 22, 2026.

• Pepsi introduced three limited-edition zero sugar ice-cream‑inspired cola flavors: Cherry & Vanilla, Raspberry Ripple and Salted Caramel.
• The campaign features an animated ice-cream pigeon character called Pidge and uses the tagline “Deliciously, confusingly. Not real ice-cream.”
• Launch support includes a nationwide sampling tour and immersive pop-up experiences in London and Brighton.

10-Q Financial Filing Analysis for Pfizer (2026-08-04)

Pfizer Inc. reported its second-quarter 2026 financial results, with total revenues rising 3% year-over-year to $15.03 billion (up 1% operationally). Operational expansion was led by core franchises including Eliquis (+19% operationally to $2.43 billion), Padcev (+23% operationally to $667 million), and the Vyndaqel family (+8% operationally to $1.76 billion), which offset steep declines in COVID-19 product revenues (Paxlovid down 95% operationally to $21 million; Comirnaty down 34% operationally to $261 million). The company reported a net loss attributable to common shareholders of $(248) million for Q2 2026, compared to net income of $2.91 billion in Q2 2025. This downturn was driven by $4.33 billion in pre-tax intangible asset impairment charges (including $3.8 billion for sigvotatug vedotin following unfavorable Phase 3 trial results and $525 million for Oxbryta), alongside $842 million in legal charges, partially offset by a $1.87 billion net gain on the exit of its ViiV Healthcare investment. Pfizer also expanded its enterprise-wide cost realignment and manufacturing optimization programs, targeting total net cost savings of approximately $6.7 billion and $3.0 billion, respectively, through 2029.

• Q2 2026 total revenues reached $15.03 billion, up 3% YoY (5% operational growth excluding COVID-19 products Comirnaty and Paxlovid).
• Net loss attributable to common shareholders was $(248) million, heavily impacted by $4.325 billion in intangible asset impairments ($3.8 billion for IPR&D sigvotatug vedotin and $525 million for Oxbryta) and $842 million in legal charges.
• Pfizer completed the sale of its 11.7% stake in ViiV Healthcare for $1.875 billion in cash proceeds, realizing a pre-tax net gain of $1.870 billion.

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Investor Presentation Released: Pfizer

AI parsed presentation narrative: Pfizer is demonstrating steady execution and financial outperformance by exceeding revenue and EPS expectations despite the decline in COVID-19 product sales. Management's central thesis focuses on maximizing the value of key acquisitions like Seagen and Metsera to drive post-2028 growth through a high single-digit revenue CAGR and a robust pipeline in oncology and obesity. Key tailwinds mentioned: Acquisition Integration Success, Obesity Pipeline Advancement.